证券代码：839273 证券简称：一致魔芋 公告编号：2025-024 本次股东大会的召集人为董事会。 一、会议召开基本情况 本次会议采用现场投票和网络投票相结合方式召开。 （一）股东大会届次 本次会议为 2024 年年度股东大会。 （二）召集人 （三）会议召开的合法性、合规性 本次会议的召开符合《中华人民共和国公司法》等有关法律、法规以及《公 司章程》的规定。 湖北一致魔芋生物科技股份有限公司 （四）会议召开方式 关于召开 2024 年年度股东大会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 2. 本公司董事、监事、高级管理人员。 公司同一表决权只能选择现场、网络投票中的一种。同一表决权出现重复 表决的以第一次投票结果为准。 （五）会议召开日期和时间 1、现场会议召开时间：2025 年 4 月 15 日 15:00。 2、网络投票起止时间：2025 年 4 月 14 日 15:00—2025 年 4 月 15 日 15:00。 登记在册的股东可通过中国证券登记结算有限责任公 ...

证券代码：839273 证券简称：一致魔芋 公告编号：2025-019 湖北一致魔芋生物科技股份有限公司 第三届监事会第二十次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 本次会议程序符合《公司法》及《公司章程》的有关规定，会议决议为有效 决议。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《关于公司 2024 年度监事会工作报告的议案》 1.议案内容： 公司监事会及全体监事在 2024 年度按照国家有关法律、法规和《公司章程》 的规定，认真执行股东大会各项决议，履行监事职责。根据《公司法》及《公司 1.会议召开时间：2025 年 3 月 22 日 2.会议召开地点：公司会议室 3.会议召开方式：现场会议 4.发出监事会会议通知的时间和方式：2025 年 3 月 12 日 以通讯方式发出 5.会议主持人：监事会主席万静女士 6.召开情况合法、合规、合章程性说明： 章程》的规定，公司监 ...

证券代码：839273 证券简称：一致魔芋 公告编号：2025-018 湖北一致魔芋生物科技股份有限公司 第三届董事会第二十一次会议决议公告 3.会议召开方式：现场+通讯 4.发出董事会会议通知的时间和方式：2025 年 3 月 12 日以通讯方式发出 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 3 月 22 日 2.会议召开地点：公司会议室 5.会议主持人：董事长吴平女士 6.会议列席人员：全体监事 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开符合《公司法》《公司章程》《董事会议事规则》的相 关规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事李力、彭光伟，独立董事李秉成、罗忆松、钱和因工作原因以通讯方式 参与表决。 二、议案审议情况 （一）审议通过《关于公司（2025 年-2027 年）三年战略发展规划纲要的议案》 1.议案内容： 为顺利实施公司战略，合理支配公司资源， ...

湖北一致魔芋生物科技股份有限公司 2024 年年度权益分派预案公告 证券代码：839273 证券简称：一致魔芋 公告编号：2025-022 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 为积极履行回报股东义务，与全体股东分享公司经营收益，在统筹考虑战略 发展目标及流动资金需求，保证公司持续、稳定、健康发展的前提下，湖北一致 魔芋生物科技股份有限公司（以下简称"公司"）拟实施 2024 年年度权益分派。 一、权益分派预案情况 根据公司 2025 年 3 月 24 日披露的 2024 年年度报告（财务报告已经审计）， 截至 2024 年 12 月 31 日，上市公司合并报表归属于母公司的未分配利润为 268,858,996.39 元，母公司未分配利润为 271,768,124.96 元。母公司资本公积为 245,025,953.71 元（其中股票发行溢价形成的资本公积为 250,753,221.39 元，其 他资本公积为-5,727,267.68 元）。 公司本次权益分派预案如下：公司目前总股本为 73, ...

Financial Performance - The company's operating revenue for 2024 reached ¥616,519,674.06, representing a 28.76% increase from ¥478,823,062.43 in 2023[25]. - The net profit attributable to shareholders for 2024 was ¥86,716,564.59, a 64.41% increase compared to ¥52,743,636.75 in 2023[25]. - The gross profit margin improved to 26.65% in 2024, up from 20.98% in 2023[25]. - The basic earnings per share increased by 60.81% to ¥1.19 in 2024, compared to ¥0.74 in 2023[25]. - The net profit after deducting non-recurring gains and losses surged by 164.70% to ¥82,884,272.82 in 2024 from ¥31,312,227.90 in 2023[25]. - The weighted average return on equity based on net profit attributable to shareholders was 14.80% in 2024, compared to 10.03% in 2023[25]. - The company's operating profit surged by 105.30%, reaching ¥103,499,988.80, compared to ¥50,414,646.40 in the previous year[64]. - The net profit for 2024 was ¥86,694,228.66, a 64.23% increase from ¥52,788,759.33 in 2023, driven by higher revenue and improved gross margins[63][64]. Assets and Liabilities - Total assets increased to ¥784,498,114.31, a growth of 22.22% compared to the end of 2023[27]. - Total liabilities rose significantly to ¥165,560,862.70, marking a 117.78% increase from the previous year[27]. - The company's cash flow from operating activities showed a negative net amount of ¥68,681,925.78, a decline of 147.08% compared to the previous year[27]. - The company's current ratio decreased by 63.09% to 4.37[27]. - The company reported a significant increase in accounts receivable, rising by 62.09% to ¥72,875,867.71, compared to ¥44,960,827.65 in the previous year[58]. - Inventory levels surged by 61.45%, reaching ¥435,125,322.09, up from ¥269,513,486.88 at the end of the previous year[58]. - The company's cash and cash equivalents decreased by 28.41%, totaling ¥58,754,029.58, down from ¥82,073,537.25[58]. Research and Development - The company invested ¥23,784,427.95 in research and development during the reporting period, marking a 32.17% increase compared to the previous year, with a focus on the functional properties of konjac[51]. - The total number of R&D personnel increased from 33 to 78, with the proportion of R&D staff in total employees rising from 6.90% to 12.79%[90]. - The company has completed several R&D projects, including the development of three new tea products aimed at promoting health trends in the tea beverage market[92]. - The company has developed new green processing techniques for konjac beauty products, resulting in three new products and improved market recognition[94]. - Research on the nutritional value of konjac powder has led to the development of six or more new products, enhancing the company's product offerings[95]. Market and Industry - The market for konjac products has a compound annual growth rate (CAGR) of 26% over the past decade, indicating strong growth potential[55]. - The konjac industry is supported by government policies, financial support, and industry guidance to promote standardized and large-scale development[53]. - The company is focusing on both B2B raw materials and B2C food and beauty products to ensure stable growth[56]. - The company aims to enhance the quality of konjac powder and expand its applications, transitioning from a raw material manufacturer to an application service provider[108]. - The konjac industry is experiencing steady growth, driven by increasing consumer demand for healthy food, with expectations for continued market demand due to the unique nutritional value of konjac products[105]. Governance and Compliance - The company has established governance structures to mitigate risks associated with the actual controllers potentially influencing company decisions[112]. - The company is committed to maintaining compliance with the Company Law and Securities Law in its governance practices[192]. - The governance mechanism ensures that all shareholders have appropriate protection and equal rights, with voting procedures compliant with legal requirements[186]. - The company has established a special report on the use of raised funds, ensuring transparency in fund management[191]. - The company has implemented an investor relations management system to enhance communication with existing and potential investors, aiming to protect their rights and maximize shareholder value[194]. Shareholder and Stock Information - The total number of shares held by the top ten shareholders is 55,234,444, accounting for 74.89% of total shares[139]. - The largest shareholder, Wu Ping, holds 19,590,000 shares, representing 26.56% of total shares[139]. - The company has a cash dividend policy that stipulates a minimum of 10% of the distributable profit for the year must be distributed in cash, and at least 30% over three consecutive years[154]. - For the 2023 fiscal year, the company distributed CNY 3.00 per 10 shares to shareholders, based on a total of 72,399,016 shares eligible for distribution[155]. - The company has a total of 610 employees at the end of the reporting period, an increase of 132 employees from the beginning of the period[173]. Risk Management - The company faces risks related to its reliance on konjac powder sales, which may limit flexibility in response to market changes[111]. - The company is exposed to price volatility of raw materials, particularly konjac, which significantly impacts production costs[112]. - The company has implemented measures to mitigate supplier risks by evaluating existing suppliers and establishing a backup supplier resource pool[8]. - The company is actively monitoring foreign exchange market trends and implementing measures to mitigate the impact of exchange rate fluctuations on financial results[113]. - The company has established a comprehensive quality control system, achieving multiple certifications including FSSC22000, HACCP, and ISO9001:2015, ensuring product safety and quality[8].

Group 1: Market Performance - As of February 28, 2025, the North Exchange 50 Index closed at 1306.98 points, reflecting a weekly decline of 2.85%[28] - The average PE ratio for North Exchange A-shares increased to 43.69X, while the PE ratios for the Sci-Tech Innovation Board and the ChiNext decreased to 54.52X and 37.77X, respectively[23] - The average daily trading volume for North Exchange A-shares reached 34.541 billion yuan, up 7.41% from the previous week[24] Group 2: Fund Performance - Multiple North Exchange theme funds reached new net asset value highs, with 12 funds achieving this milestone on February 27, 2025[14] - The average return for North Exchange theme funds in 2025 has reached 24.16%, significantly higher than the 2024 annual return of 14.52%[18] - The average returns for passive index funds related to North Exchange 50, Sci-Tech Innovation 50, CSI 300, and ChiNext were 28.01%, 12.64%, 1.13%, and 5.35%, respectively[20] Group 3: IPO and Valuation Insights - As of February 28, 2025, there were 122 companies on the North Exchange with a PE TTM exceeding 45X, accounting for 46.21% of the total[32] - The number of companies with a PE TTM in the range of 0-30X decreased by 6 compared to the previous peak in November 2024[32] - One company terminated its IPO registration, while another company has completed its registration as of February 28, 2025[4]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][4] Core Views - The company's 2024 performance is expected to show significant growth, with a projected 64% year-on-year increase in net profit attributed to rising sales of konjac powder and snacks [4][5] - The company is expanding its product applications in the konjac sector, particularly in the snack food market, which has seen a 166.77% increase in sales year-on-year for konjac snacks in 2024 [5] - The company is progressing with its 80,000-ton konjac ball project, with plans for equipment commissioning and production by 2025 [5] Financial Summary - The company's revenue for 2024 is projected to be 617 million yuan, a 28.8% increase from 2023, with net profit expected to reach 87 million yuan, reflecting a 64.4% increase [7][12] - The gross margin is expected to stabilize around 24% in 2024, while the net margin is projected to be 14.1% [12] - Earnings per share (EPS) are forecasted to be 1.18 yuan in 2024, with a price-to-earnings (P/E) ratio of 23.9 [7][12] Market Dynamics - The market demand for konjac products is increasing, driven by consumer recognition and the expansion of application areas [5][6] - The price of fresh konjac is projected to be around 7,600 yuan per ton in December 2024, with a favorable economic return from konjac farming [6] - The company has secured stable orders from leading brands and is actively seeking to expand its customer base [5]

Financial Performance - The company's operating revenue for the reporting period is approximately ¥616.52 million, representing a year-on-year increase of 28.76%[4] - The net profit attributable to shareholders is approximately ¥86.72 million, showing a year-on-year growth of 64.41%[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses is approximately ¥82.88 million, with a significant increase of 164.70% year-on-year[4] - Basic earnings per share are estimated at ¥1.18, reflecting a year-on-year increase of 59.46%[4] - Total assets at the end of the reporting period are approximately ¥784.50 million, up 22.22% from the beginning of the period[4] - Shareholders' equity attributable to the company is approximately ¥628.13 million, marking a year-on-year increase of 10.97%[4] Sales and Marketing - The company's marketing strategies have effectively enhanced customer awareness of the health benefits and application characteristics of konjac, leading to increased sales[6] - The growth in sales volume and price of konjac powder significantly contributed to the profit increase, along with a rapid rise in sales of konjac snacks and tea ingredients[6] Cautionary Notes - The company cautions that the financial data presented is preliminary and has not been audited, urging investors to be cautious[7] - The final data will be disclosed in the official 2024 annual report, which will supersede this preliminary announcement[7]

五矿证券有限公司（以下简称"五矿证券"、"保荐机构"）作为湖北一致魔 芋生物科技股份有限公司（以下简称"一致魔芋"或"公司"）向不特定合格投资 者公开发行股票并在北京证券交易所（以下简称"北交所"）上市的保荐机构， 根据《证券发行上市保荐业务管理办法》《北京证券交易所股票上市规则（试 行）》《北京证券交易所证券发行上市保荐业务管理细则》等相关法津、法规和 规范性文件的规定，对一致魔芋部分募集资金投资项目结项及延期的事项进行 审慎核查，具体情况如下： 一、募集资金基本情况 五矿证券有限公司关于 湖北一致魔芋生物科技股份有限公司 部分募集资金投资项目结项及延期的核查意见 本项目结项后，公司仍将保留项目募集资金专户，待支付款项将继续存 放于募集资金专户，按照募集资金管理的相关法规、规范性文件及公司《募 集资金管理办法》的规定进行监管，直至待支付款项支付完毕，届时按要求 将募集资金专户注销。 （二）部分募集资金投资项目延期 经中国证券监督管理委员会批准，一致魔芋根据《关于同意湖北一致魔 芋生物科技股份有限公司向不特定合格投资者公开发行股票注册的批复》(证 监许可[2023]18 号)，向不特定合格投资者公开发行人民币 ...